Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Helixmith Co., Ltd (084990.KQ)
Seoul, KR
Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addressing therapeutic areas like cardiovascular ailments, cancer, and immune system disorders. Its clinical research activities are actively conducted across the United States, South Korea, and China. A cornerstone of its product portfolio is VM202, a groundbreaking DNA-based drug designed for treating both cardiovascular and neurological conditions. Additionally, Helixmith's developmental compounds include VM206, a therapeutic vaccine targeting HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered variant of interleukin 11 aimed at alleviating chemotherapy-induced thrombocytopenia. Its ongoing clinical trials encompass VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Founded in 1996, the company adopted the name Helixmith Co., Ltd in April 2019, transitioning from its former identity as ViroMed Co., Ltd. The organization's main office is located in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.18% | -12.38% | -13.99% | +2.34% | +28.62% | +16.06% | +136.42% | -15.24% | -74.72% | -90.61% | -52.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-47.8% Q1'26: -40.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+97.1% ★ Q1'26: +8.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-448.1% Q1'26: -238.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-381.0% Q1'26: -396.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-16.5% Q1'26: -14.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.70B
est: 6.00B (+28.3%)
|
6.84B
est: 8.00B (-14.4%)
|
3.16B
est: 7.00B (-54.9%)
|
3.13B
est: 8.00B (-60.9%)
|
4.45B
est: 3.77B (+18.2%)
|
4.25B
est: 6.64B (-36.0%)
|
2.32B
est: 2.64B (-12.3%)
|
2.80B
est: 4.08B (-31.4%)
|
4.20B
est: 3.07B (+36.8%)
|
4.97B
est: 3.22B (+54.3%)
|
| EBITDA |
856.30M
est: -6.00B (+114.3%)
|
-1.58B
est: -8.00B (+80.2%)
|
-5.96B
est: -7.00B (+14.9%)
|
-27.67B
est: -8.00B (-245.9%)
|
-99.52B
est: -3.77B (-2,539.8%)
|
-41.29B
est: -6.64B (-521.7%)
|
-52.99B
est: -2.64B (-1,906.8%)
|
-30.49B
est: -4.08B (-647.0%)
|
-53.00B
est: -3.07B (-1,626.2%)
|
-11.09B
est: -3.22B (-244.0%)
|
| EBIT |
317.39M
est: -6.00B (+105.3%)
|
-1.98B
est: -8.00B (+75.2%)
|
-6.42B
est: -7.00B (+8.3%)
|
-28.24B
est: -8.00B (-253.0%)
|
-102.29B
est: -3.77B (-2,613.2%)
|
-53.17B
est: -6.64B (-700.6%)
|
-61.89B
est: -2.64B (-2,243.7%)
|
-40.93B
est: -4.08B (-902.9%)
|
-63.70B
est: -3.07B (-1,974.5%)
|
-15.32B
est: -3.22B (-375.3%)
|
| Net Income |
256.98M
est: -493.53M (+152.1%)
|
-714.46M
est: 2.31B (-131.0%)
|
-6.50B
est: -3.26B (-99.0%)
|
-28.73B
est: 97.44B (-129.5%)
|
-107.04B
est: -70.27B (-52.3%)
|
-82.86B
est: -60.86B (-36.1%)
|
-70.22B
est: -52.54B (-33.6%)
|
-43.54B
est: -59.53B (+26.9%)
|
-64.09B
est: -63.10B (-1.6%)
|
-15.47B
est: -64.34B (+76.0%)
|
| SGA |
4.36B
est: 32.00B (-86.4%)
|
4.56B
est: 42.67B (-89.3%)
|
2.19B
est: 37.34B (-94.1%)
|
4.99B
est: 42.67B (-88.3%)
|
4.63B
est: 20.11B (-77.0%)
|
19.03B
est: 35.43B (-46.3%)
|
23.00B
est: 14.09B (+63.3%)
|
23.30B
est: 21.77B (+7.0%)
|
10.92B
est: 16.38B (-33.3%)
|
6.65B
est: 15.17B (-56.1%)
|
| EPS |
9.38
est: -10.50 (+189.4%)
|
-26.26
est: 49.05 (-153.5%)
|
-218.11
est: -69.41 (-214.2%)
|
-964.66
est: 2,072.06 (-146.6%)
|
-3,563.91
est: -1,494.29 (-138.5%)
|
-2,556.68
est: -1,294.19 (-97.6%)
|
-1,864.54
est: -1,117.35 (-66.9%)
|
-1,153.75
est: -1,265.89 (+8.9%)
|
-1,543.76
est: -1,341.94 (-15.0%)
|
-329.00
est: -1,395.94 (+76.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 299.96 | 0.33% |
| 2 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 5.9K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jong-Mook Kim | Director of Devel. Division & Strategic Bus. Division and Director | — | — |
| Jun Tae Park | Executive Vice President of Licensing & Regulatory Affairs | — | — |
| Michael Na | Chief Financial Officer & Director of Office of Strategic Net Assessment | — | male |
| Miwon Son | Senior Managing Director of Phytotherapeutics | — | — |
| Seung-Shin Yu | Chief Technology Officer , Representative Director, MD of R&D Center and Intellectual Property & Director | — | male |
| Sunyoung Kim | Founder, Chief Executive Officer & Director | — | male |
| William O. Frank | Head of Medical | — | — |
| Won Park | Pres | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 084990.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
